OVARIAN CANCER RESEARCH FUND INC

As filed

Subsection

03

NTEE code

T70Z

Classification

1000

Street

45 ROCKEFELLER PLAZA 20TH FLOOR

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2025

• OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES.OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. IN 2025, THERE WERE 20,890 NEW CASES OF OVARIAN CANCER AND 12,730 DEATHS FROM THE DISEASE IN THE UNITED STATES. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN AND GYNECOLOGIC CANCER COMMUNITIES. SINCE 1998, OCRA HAS AWARDED 457 GRANTS FOR OVARIAN AND RELATED CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 103 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $137 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN AND RELATED CANCERS TO DETERMINE THE ORIGINS, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND EFFECTIVE IMMUNOTHERAPY TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, PREVENTING RECURRENCE AND METASTASIS AND ENHANCE PATIENTS' QUALITY OF LIFE. IN ADDITION TO OCRA'S ESTABLISHED RESEACH GRANT PROGRAM, OCRA ALSO CONTINUED THE HEALTH EQUITY RESEARCH GRANTS BEGUN IN 2023. THESE GRANTS FOCUS ON IMPROVING HEALTH EQUITY IN THE GYNECOLOGIC CANCER SPACE. AS PART OF OUR GLOBAL GYNECOLOGIC CANCER CONSORTIUM, MADE UP OF PARTNERS FROM THE UK, AUSTRALIA AND CANADA, OCRA LAUNCHED A NEW AI GRANT IN 2025. THE FIRST GRANT WAS AWARDED IN 2025 WITH A START DATE OF 2026. AND WITH THE RIVKIN CENTER JOINING OCRA IN 2025, THE FORMER RIVKIN PILOT GRANTS WERE ADDED, AS WELL. ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE:IDENTIFIED A MOLECULE THAT COULD BE KEY TO IMPROVING IMMUNE RESPONSE AGAINST OVARIAN CANCER; SOUGHT TO UNDERSTAND WHY CERTAIN OVARIAN CANCER CELLS RESIST OLAPARIB TREATMENT, AND DISCOVERED THAT INTRODUCING A SECOND DRUG (MIFEPRISTONE) WHILE TARGETING CERTAIN CELLS (POLYPLOID GIANT CANCER CELLS) MAY OFFER A SOLUTION; IDENTIFIED A PREVIOUSLY UNKNOWN CHEMORESISTANT PATHWAY IN HGSC WHICH LED TO WORKING ON A NEW THERAPY TO OVERCOME THIS; SHED NEW LIGHT ON HOW THE MOST COMMON SUBTYPE OF OVARIAN CANCER DEVELOPS AND METASTASIZES, BY IDENTIFYING A KEY MOLECULE THAT ALLOWS MALIGNANCIES IN THE FALLOPIAN TUBE TO MIGRATE TO THE OVARIES AND CONTINUE TO GROW; UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE TO HELP EXPLAIN SOME OVARIAN CANCERS' RESISTANCE TO IMMUNOTHERAPY; SHOWED THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER; USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC; DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186); FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL; SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK; UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE TO HELP EXPLAIN SOME OVARIAN CANCERS' RESISTANCE TO IMMUNOTHERAPY; FOUND A DECREASE IN OVARIAN CARCINOMA INCIDENCE AFTER SALPINGECTOMY FOR TREATING ECTOPIC PREGNANCY; SHOWED PARP1 IS INVOLVED IN REPAIR OF TELOMERES, AND THAT IMPAIRING THIS PROCESS CAN LEAD TO TELOMERE SHORTENING AND GENOMIC INSTABILITY THAT CAN CAUSE CANCER; DEVELOPED A PROOF-OF-CONCEPT STUDY TO SHOW HOW THREE-DIMENSIONAL MODELING CAN SHOW HOW CANCER CELLS AND CAR-T INTERACT WHICH WILL HOPEFULLY LEAD TO BETTER TREATMENTS IN PATIENTS WITH HGSOC SOLID TUMORS; DISCOVERED THAT AGGRESSIVE OVARIAN CANCERS OFTEN SHOW SUDDEN LARGE-SCALE DNA DAMAGE, POINTING TO DISTINCT ORIGINS AND DETECTION STRATEGIES; AND IDENTIFIED THAT LOSS OF A GENE CALLED SMARCA4 MAKES OVARIAN CANCER CELLS MORE VISIBLE TO THE IMMUNE SYSTEM, BOOSTING IMMUNE ATTACK AND SUGGESTING A NEW STRATEGY TO IMPROVE IMMUNOTHERAPY.IN 2025 ALONE, OCRA RESEARCHERS: DEVELOPED A PIONEERING AI TOOL TO BETTER PREDICT TREATMENT RESPONSE, A STEP TOWARD EARLIER PERSONALIZED TREATMENT PLANS; SYSTEMATICALLY TESTED EXISTING THERAPIES TO FIND AN EFFECTIVE DRUG COMBINATION THAT SHOWS PROMISE; UNCOVERED KEY DIFFERENCES IN IMMUNE ENVIRONMENTS BETWEEN PRIMARY TUMORS AND METASTASES THAT MAY EXPLAIN WHY HIGH-GRADE SEROUS OVARIAN CARCINOMA OFTEN SUPPRESSES THE IMMUNE SYSTEM; FOUND THAT MUCINOUS OVARIAN CANCERS WITH KEY GENE CHANGES WERE ASSOCIATED WITH WORSE SURVIVAL EVEN AT EARLY STAGES, SUGGESTING GENETIC TESTING AT DIAGNOSIS MAY HELP GUIDE CARE AND PREDICT OUTCOMES; DISCOVERED THAT BLOCKING A KEY NUTRIENT WHILE ALSO USING IMMUNOTHERAPY COULD OFFER A PROMISING NEW TREATMENT STRATEGY FOR AROUND HALF OF OVARIAN CLEAR CELL CANCERS; FOUND THAT AMONG PEOPLE DIAGNOSED WITH AN EARLY OVARIAN CANCER PRECURSOR, OLDER PATIENTS AND BLACK PATIENTS FACE WORSE SURVIVAL, UNDERSCORING THE URGENT NEED FOR MORE TAILORED CARE AND TREATMENT STRATEGIES; FOUND THAT PROBIOTIC SUPPLEMENTS MAY HELP GYNECOLOGIC CANCER PATIENTS REDUCE RADIATION-RELATED GUT SIDE EFFECTS; FOUND THAT A SPECIFIC DNA-REPAIR PROTEIN HELPS CANCER CELLS GROW BY SWITCHING ON A GROWTH PATHWAY, HINTING AT A POTENTIAL TREATMENT TARGET TO MAKE TUMORS MORE TREATABLE WHILE SPARING HEALTHY CELLS; FOUND THAT ENGINEERED IMMUNE CELLS WORKED MUCH BETTER IN COMBINATION WITH THREE IMMUNOTHERAPIES, ALLOWING THE IMMUNE CELLS TO STAY ACTIVE LONGER AND KILL OVARIAN CANCER IN MICE MORE EFFECTIVELY; SHOWED THAT OVARIAN CANCER RECURRENCE IS DRIVEN BY A SMALL NUMBER OF PRE-EXISTING, TREATMENT-RESISTANT CANCER CELL CLONES WHICH ARE DETECTABLE THROUGH A NEW BLOOD TEST THAT MAY PAVE THE WAY TO PREVENTING RECURRENCE; FOUND THAT SPECIALLY ENGINEERED T CELLS THAT SECRETE "BITE" MOLECULES, WHEN COMBINED WITH OTHER IMMUNOTHERAPIES, CAN TRIGGER STRONG AND LASTING ANTI-TUMOR IMMUNE RESPONSES AGAINST OVARIAN CANCER IN MICE; FOUND A WAY TO REPROGRAM MACROPHAGES TO MAKE THE IMMUNE SYSTEM FIGHT THE CANCER AGAIN; DISCOVERED A WAY TO SELECTIVELY REMOVE CERTAIN "PRO-CANCER" IMMUNE CELLS IN OVARIAN TUMORS BY TARGETING A SPECIFIC POCKET ON THE RETINOBLASTOMA (RB) PROTEIN, WHICH HELPS THE IMMUNE SYSTEM FIGHT THE CANCER MORE EFFECTIVELY; CREATED THE FIRST STANDARDIZED SET OF GUIDELINES, TOOLS, AND REFERENCE DATASETS FOR SPATIAL TRANSCRIPTOMICS EXPERIMENTS TO HELP SCIENTISTS COMPARE RESULTS ACROSS LABS AND MEASURE THE QUALITY AND RELIABILITY; UNCOVERED THE RULES THAT GUIDE IMMUNE CELL SIGNALING AND USED THIS KNOWLEDGE TO PROVIDE A WEB RESOURCE TO FACILITATE PROTEIN DESIGN EFFORTS, WHICH CAN BE USED TO DEVELOP NEW IMMUNE-BASED THERAPIES.EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG.

  Expenses $10,447,492 · Grants $8,681,352

• IN 2025, OVARIAN CANCER RESEARCH ALLIANCE (OCRA) PROVIDED COMPREHENSIVE EDUCATION, SUPPORT, AND NAVIGATION SERVICES TO THOUSANDS OF INDIVIDUALS AFFECTED BY OVARIAN AND GYNECOLOGIC CANCERS. OCRA'S PATIENT SUPPORT TEAM RESPONDED TO 4,237 PATIENT AND CAREGIVER CONTACTS THROUGH OUR PATIENT SUPPORT LINE, A 68% INCREASE FROM 2024, PROVIDING EMOTIONAL SUPPORT, INFORMATION, CLINICAL TRIAL GUIDANCE, PEER MENTORING, AND CARE NAVIGATION. OCRA'S WOMAN TO WOMAN PEER MENTOR PROGRAM CONTINUED TO CONNECT NEWLY DIAGNOSED PATIENTS WITH TRAINED SURVIVOR MENTORS THROUGH 19 ACTIVE SITES NATIONWIDE AND A NATIONAL VIRTUAL MATCHING PROGRAM. SINCE ITS LAUNCH, THE PROGRAM HAS FACILITATED MORE THAN 2,800 MENTOR MATCHES. IN 2025, THE NATIONAL TEAM COMPLETED 103 MATCHES AND SUPPORTED 167 MENTORS. OCRA ALSO PROVIDED INDIVIDUALIZED COUNSELING THROUGH ITS STEPS 1:1 COUNSELING PROGRAM AND FACILITATED ONGOING SUPPORT THROUGH STAYING CONNECTED, WHICH ENGAGED 3,530 PARTICIPANTS IN VIRTUAL SUPPORT AND EXPRESSIVE ARTS PROGRAM DURING THE YEAR. TO ADDRESS THE EDUCATIONAL NEEDS OF PATIENTS AND CAREGIVERS, OCRA DELIVERED ITS INTERNATIONAL GYNECOLOGIC CANCER CONFERENCE, WEBINARS, WORKSHOPS, ROUNDTABLES, AND MONTHLY EDUCATIONAL PROGRAMS FOCUSED ON DIAGNOSIS, TREATMENT ADVANCES, SURVIVORSHIP, BIOMARKER TESTING, AND CLINICAL TRIALS. OFFERED FREE OF CHARGE FOR THE FIRST TIME, OCRA'S INTERNATIONAL GYNECOLOGIC CANCER CONFERENCE EXPANDED ITS REACH TO MORE THAN 2,100 PARTICIPANTS WORLDWIDE. NEARLY 300 INDIVIDUALS PARTICIPATED IN OCRA'S EDUCATIONAL WORKSHOPS, INCLUDING OVARIAN CANCER 101, ENDOMETRIAL/UTERINE CANCER 101, AND SURVIVORSHIP SERIES, WHILE NATIONAL WEBINARS REACHED ALMOST 900 PARTICIPANTS. OCRA'S NEW STAYING CURRENT EDUCATIONAL SERIES PROVIDED DISEASE-SPECIFIC UPDATES AND CLINICAL TRIAL INFORMATION TO MORE THAN 200 PARTICIPANTS. COLLECTIVELY, OCRA'S EDUCATIONAL PROGRAMS REACHED MORE THAN 4,000 PARTICIPANTS IN 2025, PROVIDING TIMELY, EVIDENCE-BASED INFORMATION TO HELP PATIENTS AND CAREGIVERS MAKE INFORMED DECISIONS THROUGHOUT THEIR CANCER JOURNEY.IN ADDITION TO ITS SUPPORT AND EDUCATION PROGRAMS, OCRA OFFERS FREE GENETIC TESTING TO QUALIFIED HIGH-RISK INDIVIDUALS AND FACILITATES ACCESSS TO CERTIFIED GENETIC COUNSELORS. SINCE THE PROGRAM'S INCEPTION, OCRA HAS HELPED MORE THAN 3,000 INDIVIDUALS BETTER UNDERSTAND THEIR INHERITED RISK FOR OVARIAN AND OTHER GYNECOLOGIC CANCERS, EMPOWERING THEM AND THEIR FAMILIES TO MAKE INFORMED HEALTHCARE DECISIONS. ADDITIONALLY, OCRA'S CLINICAL TRIAL NAVIGATOR CONTINUED TO EXPAND ACCESS TO CLINICAL TRIAL INFORMATION, WITH 1,540 COMPLETED QUESTIONNAIRES AND MORE THAN 11,700 WEBSITE VISITS IN 2025.OCRA IS ALSO COMMITTED TO DEVELOPING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS DEDICATED TO IMPROVING OUTCOMES FOR INDIVIDUALS DIAGNOSED WITH GYNECOLOGIC CANCERS. THROUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT PROGRAM, MASTER OF SOCIAL WORK CANDIDATES RECEIVE SPECIALIZED TRAINING AND SUPERVISION FROM LICENSED CLINICAL SOCIAL WORKERS, GAINING EXPERIENCE ADDRESSING THE UNIQUE PSYCHOLOGICAL, EMOTIONAL, AND PRACTICAL NEEDS OF PATIENTS AND CAREGIVERS AFFECTED BY GYNECOLOGIC CANCERS.OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. IN 2025, MORE THAN 930 SURVIVOR VOLUNTEERS DELIVERED MORE THAN 400 PRESENTATIONS IN THE US, UK, AND AUSTRALIA REACHING OVER 10,627 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS ENSURE THE NEXT GENERATION OF HEALTH CARE PROVIDERS UNDERSTAND BASIC FACTS ABOUT THE DISEASE, ARE AWARE OF RISK FACTORS, AND CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS.THROUGH THESE PROGRAMS, OCRA EMPOWERS PATIENTS AND CAREGIVERS WITH TRUSTED INFORMATION, EMOTIONAL SUPPORT, AND CONNECTIONS TO RESOURCES THAT IMPROVE QUALITY OF LIFE AND INFORMED DECISION-MAKING FROM DIAGNOSIS THROUGH SURVIVORSHIP AND BEYOND.

  Expenses $3,162,885

• OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES FOR EVERYONE TOUCHED BY GYNECOLOGIC CANCER. IN 2025, OCRA ESTABLISHED ITS CENTER FOR PUBLIC POLICY TO EXPAND POLICY EDUCATION, LEGISLATIVE TRACKING, AND ADVOCACY ENGAGEMENT OPPORTUNITIES FOR PATIENTS, CAREGIVERS, AND SUPPORTERS NATIONWIDE. OCRA TRAINED AND MOBILIZED MORE THAN 160 ADVOCATES AND SUPPORTERS TO ENGAGE IN THE POLICYMAKING PROCESS. NEARLY 120 ADVOCATES FROM 35 STATES AND THE DISTRICT OF COLUMBIA PARTICIPATED IN OCRA'S ADVOCACY DAY, CONDUCTING MORE THAN 135 MEETINGS WITH CONGRESSIONAL OFFICES. THROUGH 12 GRASSROOTS ACTION ALERTS, ADVOCATES GENERATED MORE THAN 21,000 MESSAGES TO POLICYMAKERS, AND MORE THAN 6,000 NEW ADVOCATES JOINED OCRA'S ADVOCACY NETWORK. OCRA'S ADVOCACY CONTRIBUTED TO PRESERVING FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION PROGRAMS, SUPPORTED ENACTMENT OF STATE BIOMARKER ACCESS LAWS, SECURED BIPARTISAN CONGRESSIONAL SUPPORT FOR INCREASED OVARIAN CANCER RESEARCH FUNDING, AND HELPED OBTAIN MORE THAN 120 PROCLAMATIONS AND RESOLUTIONS RECOGNIZING OVARIAN CANCER AWARENESS MONTH.

  Expenses $595,806

As filed on the 2025 return. The filer continues this part on Schedule O, which is not shown here.

Officers and directors · 2025

As listed in Part VII of the 2025 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

• JOHN ORRICO

  CHAIR

  Total calculated

  $0

  Hours/week

  3

• MATTHEW NEAL MILLER

  VICE PRESIDENT

  Total calculated

  $0

  Hours/week

  2

• MARK TESSAR

  TREASURER

  Total calculated

  $0

  Hours/week

  2

• ROBIN S COHEN

  SECRETARY

  Total calculated

  $0

  Hours/week

  2 + 0.1 related

• DEBRA BIRNBAUM

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• JEANNETTE CHANG

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• CARMEL J COHEN MD

  DIRECTOR THRU AUG 2025

  Total calculated

  $0

  Hours/week

  1

• ANDREW FEUERSTEIN ESQ

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• CAROL J HAMILTON

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• JOHN W HANSBURY ESQ

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1 + 0.1 related

• CAROLINE HIRSCH

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• VERONICA JORDAN

  DIRECTOR THRU SEPT 2025

  Total calculated

  $0

  Hours/week

  1

• THOMAS C LIEBMAN

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• DANA L MARK ESQ

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• CHRIS NEWCOMB

  DIRECTOR THRU DEC 2025

  Total calculated

  $0

  Hours/week

  1

• MELISSA RIVKIN

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• LISA SCHREIBER

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• LAURA SHAWVER

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• MEI-LI DA SILVA VINT ESQ

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• ELLE SIMONE SCOTT

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• CHRISTOPHER TILBERIS

  DIRECTOR

  Total calculated

  $0

  Hours/week

  1

• AUDRA L MORAN

  PRESIDENT & CEO

  Total calculated

  $368,755

  From this org

  $333,548

  From related orgs

  $0

  Other

  $35,207

  Hours/week

  40 + 0.1 related

  Schedule J breakdown matched by us

  Base

  $333,548

  Bonus

  $0

  Other

  $0

  Deferred

  $13,342

  Nontaxable benefits

  $21,865

  Filer's total

  $368,755

• JONATHAN ZEIDMAN

  CHIEF DEVELOPMENT OFFICER

  Total calculated

  $245,428

  From this org

  $201,949

  From related orgs

  $0

  Other

  $43,479

  Hours/week

  40

  Schedule J breakdown matched by us

  Base

  $201,949

  Bonus

  $0

  Other

  $0

  Deferred

  $0

  Nontaxable benefits

  $43,479

  Filer's total

  $245,428

• SARAH C DEFEO

  CHIEF PROGRAM OFFICER

  Total calculated

  $241,025

  From this org

  $171,149

  From related orgs

  $0

  Other

  $69,876

  Hours/week

  40

  Schedule J breakdown matched by us

  Base

  $171,149

  Bonus

  $0

  Other

  $0

  Deferred

  $7,839

  Nontaxable benefits

  $62,037

  Filer's total

  $241,025

• TRACY MOORE

  VICE PRESIDENT, SUPPORT & EDUCATION

  Total calculated

  $190,788

  From this org

  $162,573

  From related orgs

  $0

  Other

  $28,215

  Hours/week

  40

  Schedule J breakdown matched by us

  Base

  $162,573

  Bonus

  $0

  Other

  $0

  Deferred

  $6,503

  Nontaxable benefits

  $21,712

  Filer's total

  $190,788

The first 25 listed. Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

• 2025

  Revenue

  $19,532,836

  Expenses

  $17,338,069

  Contributions

  $17,855,600

  Grants paid

  $8,681,352

• 2024

  Revenue

  $10,047,998

  Expenses

  $13,556,516

  Contributions

  $8,538,194

  Grants paid

  $6,428,064

• 2023

  Revenue

  $13,442,515

  Expenses

  $13,752,760

  Contributions

  $11,556,311

  Grants paid

  $8,117,910

• 2023

  Revenue

  $13,442,515

  Expenses

  $13,752,760

  Contributions

  $11,556,311

  Grants paid

  $8,117,910

• 2022

  Revenue

  $16,425,940

  Expenses

  $11,462,650

  Contributions

  $15,386,443

  Grants paid

  $6,693,567

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

• 2021 · 990

  Revenue

  $13,088,201

  Expenses

  $11,092,931

  Assets (EOY)

  $32,985,153

• 2020 · 990

  Revenue

  $7,726,766

  Expenses

  $8,360,005

  Assets (EOY)

  $29,388,979

• 2019 · 990

  Revenue

  $8,409,768

  Expenses

  $10,684,965

  Assets (EOY)

  $30,448,674

• 2018 · 990

  Revenue

  $9,721,559

  Expenses

  $11,054,168

  Assets (EOY)

  $28,825,539

• 2017 · 990

  Revenue

  $11,282,276

  Expenses

  $10,805,177

  Assets (EOY)

  $32,848,561

• 2016 · 990

  Revenue

  $11,255,964

  Expenses

  $10,666,517

  Assets (EOY)

  $31,267,081

• 2015 · 990

  Revenue

  $7,138,289

  Expenses

  $8,345,217

  Assets (EOY)

  $29,913,445

• 2014 · 990

  Revenue

  $8,836,443

  Expenses

  $8,368,155

  Assets (EOY)

  $33,254,984

• 2013 · 990

  Revenue

  $9,330,930

  Expenses

  $8,633,550

  Assets (EOY)

  $32,973,277

• 2012 · 990

  Revenue

  — not reported

  Expenses

  $7,585,095

  Assets (EOY)

  $31,416,587

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all. Showing the 10 most recent; the API carries the rest.

Grants made

• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  $1,948,941

  2025 · RESEARCH

• MD ANDERSON CANCER CENTER

  $1,350,000

  2023 · RESEARCH GRANT

• OHIO STATE UNIVERSITY

  $1,333,314

  2023 · RESEARCH GRANT

• MEMORIAL SLOAN-KETTERING CANCER CENTER

  $975,000

  2022 · RESEARCH GRANT

• SAN JOSE UNIVERSITY

  $900,000

  2022 · RESEARCH GRANT

• HARVARD SCHOOL OF PUBLIC HEALTH

  $900,000

  2022 · RESEARCH GRANT

• UNIVERSITY OF MINNESOTA

  $900,000

  2024 · RESEARCH

• THE GEORGE WASHINGTON UNIVERSITY

  $900,000

  2024 · RESEARCH

• COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  $900,000

  2023 · RESEARCH GRANT

• THE UNIVERSITY OF NEW MEXICO

  $900,000

  2025 · RESEARCH

The 10 largest by cash amount. The API serves every itemized grant.

Where these grants went next →

Grants received

• CANCER RESEARCH AMERICA NFCR INC

  $500,000

  2023 · Research Grant

• PAYPAL CHARITABLE GIVING FUND

  $386,324

  2024 · GENERAL SUPPORT

• AMERICAN ONLINE GIVING FOUNDATION INC

  $169,130

  2023 · GENERAL SUPPORT

• COMMUNITY FOUNDATION OF NORTHERN NEVADA

  $160,132

  2023 · general support

• AMERICAN ONLINE GIVING FOUNDATION INC

  $152,393

  2022 · GENERAL SUPPORT

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $148,723

  2024 · For grant recipient's exempt purposes

• AMERICAN ONLINE GIVING FOUNDATION INC

  $147,966

  2024 · GENERAL SUPPORT

• DONOR ADVISED CHARITABLE GIVING

  $147,845

  2024 · PUBLIC, SOCIETAL BENEFIT

• FIDELITY INVESTMENTS CHARITABLE GIFT FUND

  $135,957

  2023 · For grant recipient's exempt purposes

• AMERICAN ENDOWMENT FOUNDATION

  $122,750

  2022 · PHILANTHROPY

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations

From Schedule R Part II, where a filer lists the tax-exempt organizations it is related to by control. It does not record shared board members or money.

Other IRS files